TNDM Tandem Diabetes Care Inc
Price (delayed)
$16.56
Market cap
$1.1B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.47
Enterprise value
$1.51B
Tandem Diabetes Care is a public US medical device manufacturer based in San Diego, CA. The company develops medical technologies for the treatment of diabetes and specifically insulin infusion therapy.
Highlights
The net income has soared by 57% YoY and by 24% from the previous quarter
Tandem Diabetes Care's EPS has soared by 57% YoY and by 24% from the previous quarter
The company's equity fell by 16% YoY but it rose by 11% QoQ
Tandem Diabetes Care's quick ratio has decreased by 24% YoY
The debt has increased by 14% YoY
Key stats
What are the main financial stats of TNDM
Market
Valuations
Earnings
Shares outstanding
66.47M
Market cap
$1.1B
Enterprise value
$1.51B
Price to earnings (P/E)
N/A
Price to book (P/B)
4.13
Price to sales (P/S)
1.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.6
Revenue
$940.2M
Gross profit
$489.57M
Operating income
-$99.13M
Net income
-$96.03M
EBIT
-$84.46M
EBITDA
-$67.85M
Free cash flow
$4.99M
Per share
Balance sheet
Liquidity
EPS
-$1.47
EPS diluted
-$1.47
Free cash flow per share
$0.08
Book value per share
$4.01
Revenue per share
$14.36
TBVPS
$14.78
Total assets
$967.66M
Total liabilities
$704.56M
Debt
$473.57M
Equity
$263.1M
Working capital
$477.44M
Debt to equity
1.8
Current ratio
2.93
Quick ratio
2.24
Net debt/EBITDA
-5.96
Margins
Efficiency
Dividend
EBITDA margin
-7.2%
Gross margin
52.1%
Net margin
-10.2%
Operating margin
-10.5%
Return on assets
-10.1%
Return on equity
-39.3%
Return on invested capital
-7.4%
Return on capital employed
-11.7%
Return on sales
-9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TNDM stock price
How has the Tandem Diabetes Care stock price performed over time
Intraday
1.28%
1 week
-4.06%
1 month
-18.38%
1 year
-52.65%
YTD
-54.03%
QTD
-13.57%
Financial performance
How have Tandem Diabetes Care's revenue and profit performed over time
Revenue
$940.2M
Gross profit
$489.57M
Operating income
-$99.13M
Net income
-$96.03M
Gross margin
52.1%
Net margin
-10.2%
The operating margin has soared by 66% YoY and by 33% from the previous quarter
The net margin has soared by 66% YoY and by 31% from the previous quarter
The net income has soared by 57% YoY and by 24% from the previous quarter
The operating income has soared by 57% YoY and by 26% QoQ
Growth
What is Tandem Diabetes Care's growth rate over time
Valuation
What is Tandem Diabetes Care stock price valuation
P/E
N/A
P/B
4.13
P/S
1.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.6
Tandem Diabetes Care's EPS has soared by 57% YoY and by 24% from the previous quarter
TNDM's price to book (P/B) is 68% less than its 5-year quarterly average of 12.6 and 60% less than its last 4 quarters average of 10.3
The company's equity fell by 16% YoY but it rose by 11% QoQ
The P/S is 83% lower than the 5-year quarterly average of 6.9 and 62% lower than the last 4 quarters average of 3.0
TNDM's revenue is up by 26% year-on-year and by 10% since the previous quarter
Efficiency
How efficient is Tandem Diabetes Care business performance
Tandem Diabetes Care's ROS has soared by 68% YoY and by 34% from the previous quarter
The return on invested capital has surged by 62% year-on-year and by 27% since the previous quarter
The return on assets has surged by 57% year-on-year and by 25% since the previous quarter
TNDM's ROE is up by 43% YoY and by 20% from the previous quarter
Dividends
What is TNDM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TNDM.
Financial health
How did Tandem Diabetes Care financials performed over time
The total assets is 37% greater than the total liabilities
Tandem Diabetes Care's quick ratio has decreased by 24% YoY
TNDM's current ratio is down by 23% year-on-year
The debt is 80% more than the equity
The company's debt to equity rose by 35% YoY but it fell by 10% QoQ
The company's equity fell by 16% YoY but it rose by 11% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.